| Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer C Dolladille, S Ederhy, M Sassier, J Cautela, F Thuny, AA Cohen, ... JAMA oncology 6 (6), 865-871, 2020 | 444 | 2020 |
| Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio‐oncology guidelines J Alexandre, J Cautela, S Ederhy, GL Damaj, JE Salem, F Barlesi, ... Journal of the American Heart Association 9 (18), e018403, 2020 | 260 | 2020 |
| Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study … PM Morice, A Leary, C Dolladille, B Chrétien, L Poulain, ... The Lancet Haematology 8 (2), e122-e134, 2021 | 206 | 2021 |
| Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis C Dolladille, J Akroun, PM Morice, A Dompmartin, E Ezine, M Sassier, ... European Heart Journal 42 (48), 4964-4977, 2021 | 129 | 2021 |
| Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization Pharmacovigilance Database LS Nguyen, C Dolladille, MD Drici, C Fenioux, J Alexandre, JP Mira, ... Circulation 142 (3), 303-305, 2020 | 121 | 2020 |
| Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors C Dolladille, S Ederhy, S Allouche, Q Dupas, R Gervais, J Madelaine, ... Journal for immunotherapy of cancer 8 (1), 2020 | 88 | 2020 |
| Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database LS Nguyen, LT Cooper, M Kerneis, C Funck-Brentano, J Silvain, ... Nature communications 13 (1), 25, 2022 | 84 | 2022 |
| Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database J Alexandre, JE Salem, J Moslehi, M Sassier, C Ropert, J Cautela, ... European Heart Journal-Cardiovascular Pharmacotherapy 7 (4), 312-320, 2021 | 68 | 2021 |
| High incidence of atrial fibrillation in patients treated with ibrutinib F Baptiste, J Cautela, Y Ancedy, N Resseguier, T Aurran, L Farnault, ... Open Heart 6 (1), e001049, 2019 | 63 | 2019 |
| The reporting of a disproportionality analysis for drug Safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration M Fusaroli, F Salvo, B Begaud, TM AlShammari, A Bate, V Battini, ... Drug safety 47 (6), 585-599, 2024 | 60 | 2024 |
| Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event J Cautela, F Rouby, JE Salem, J Alexandre, U Scemama, C Dolladille, ... Canadian Journal of Cardiology 36 (4), 476-481, 2020 | 44 | 2020 |
| Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication S Ederhy, C Dolladille, F Thuny, J Alexandre, A Cohen European journal of heart failure 21 (7), 945-947, 2019 | 43 | 2019 |
| Management of immune checkpoint inhibitor–induced myocarditis: the French Working Group’s Plea for a pragmatic approach F Thuny, J Alexandre, JE Salem, M Mirabel, C Dolladille, A Cohen-Solal, ... Cardio Oncology 3 (1), 157-161, 2021 | 40 | 2021 |
| Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis C Fenioux, B Abbar, S Boussouar, M Bretagne, JR Power, JJ Moslehi, ... Nature Medicine 29 (12), 3100-3110, 2023 | 34 | 2023 |
| Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta‐analysis, and meta‐regression to identify modifying factors J Alexandre, C Dolladille, L Douesnel, J Font, R Dabrowski, L Shavit, ... Journal of the American Heart Association 8 (22), e013267, 2019 | 33 | 2019 |
| Comparative study of hypoglycaemia induced by opioids. Is it a class effect? B Chrétien, C Dolladille, L Hamel-Sénécal, M Sassier, JL Faillie, ... Expert opinion on drug safety 18 (10), 987-992, 2019 | 30 | 2019 |
| Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase® B Chrétien, V Lelong-Boulouard, S Chantepie, M Sassier, M Bertho, ... Psychological medicine 51 (9), 1459-1466, 2021 | 29 | 2021 |
| Definition of left ventricular remodelling following ST-elevation myocardial infarction: a systematic review of cardiac magnetic resonance studies in the past decade D Legallois, A Hodzic, J Alexandre, C Dolladille, E Saloux, A Manrique, ... Heart Failure Reviews, 1-12, 2022 | 28 | 2022 |
| Association between disease-modifying therapies prescribed to persons with multiple sclerosis and cancer: a WHO pharmacovigilance database analysis C Dolladille, B Chrétien, L Peyro-Saint-Paul, J Alexandre, O Dejardin, ... Neurotherapeutics 18, 1657-1664, 2021 | 26 | 2021 |
| Chimeric antigen receptor T‐cells safety: A pharmacovigilance and meta‐analysis study C Dolladille, S Ederhy, E Ezine, S Choquet, LS Nguyen, J Alexandre, ... American Journal of Hematology 96 (9), 1101-1111, 2021 | 24 | 2021 |
